Join us at ET Re-Pharma
Summit & Awards 2026 - 6th Edition
Join us at ET Re-Pharma
Summit & Awards 2026 - 6th Edition
Experience Leucine AI .
Powered Pharma Operations

Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.

See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.

Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.

Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.

Optimize your manufacturing processes with paperless operations
Strengthen quality management and regulatory compliance
Accelerate laboratory operations and testing workflows

Connect with a Leucine Expert

Schedule a 30-Minute Product Demo with Expert Q&A

Sub System /
Annual Product Quality Review
Annual Product Quality Review
View Detailed Analysis

Analytics Overview

22
Form 483s Issued
1
483s converted to WL
22
Total Observation
Form 483s Issued
+74 from last period

Analytics Overview

Form 483 Conversion Rate by Year
Form 483s Issued (Yearly)

Recent Form 483s & Warning Letters

View all 483’s
Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
09 May 2025
LEESAR, INC
Drugs
21 Jun 2024
Brands International Corporation
Drugs
14 Nov 2023
Carma Laboratories, Inc.
Drugs
18 Oct 2023
XYZ Pharmaceuticals
Drugs
14 Oct 2023
XYZ Pharmaceuticals Inc.
Drugs

Top Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Jane Smith
11
0
John Doe
11
0
José E Melendez
3
0
Gavin T Cua
2
0
Nibin Varghese
2
1
TITLE/ COMPANY Issue Date Status Details
Records are not maintained so that data therein can be reviewed at least annually to evaluate the quality standards of each drug product to determine the need for changes in specifications or manufacturing or control procedures.
LEESAR, INC
09 May 2025 Normal Justification: The issue is directly linked to the lapses in carrying out and recording the Annual Product Quality Review, critical for maintaining drug quality.
Excerpt: your firm does not maintain written records for annual product reviews conducted for your aseptically produced drug products.
View Details
Records are not maintained so that data therein can be reviewed at least annually
Brands International Corporation
21 Jun 2024 Normal Justification: Annual Product Quality Review is directly implicated as the observation highlights deficiencies in conducting required evaluations.
Excerpt: Your firm has failed to perform annual product review for all the OTC products manufactured at your facility.
View Details
Written procedures are not followed for evaluations conducted to review records associated with batches
Carma Laboratories, Inc.
14 Nov 2023 Normal Justification: The deficiencies in conducting and closing APRs directly fall under Annual Product Quality Review as process type.
Excerpt: Specifically, Your firm failed to perform Annual Product Review (APR) for Domestic Lip Balm Stick and Domestic Lip Balm Tube for the year of 2022. According to your written procedure, individual APR are completed (b) (4) . Additionally, your procedure is deficient for the closure of APRs on a timely manner. For example, APR for Domestic Lip Balm Stick review period (1/1/2021 - 12/31/2021) was not completed until 12/29/2022.
View Details
Failure to ensure that all test procedures listed in the annual product review are completed
XYZ Pharmaceuticals
18 Oct 2023 Normal Justification: The annual product review process is key for evaluating ongoing product quality; missing test data directly affects this evaluation.
Excerpt: The 2022 Annual Product Review for Product B omitted the dissolution test results for three consecutive batches.
View Details
Failure to conduct at least an annual review, conducted under the supervision of the quality control unit, of records
XYZ Pharmaceuticals Inc.
14 Oct 2023 Normal Justification: The observation is linked to Annual Product Quality Review as it highlights missing documentation for 2 years, crucial for quality evaluations.
Excerpt: the annual product review for [redacted] for the past 2 years has not been documented.
View Details

Prepare Better for FDA Audits with FDA Tracker

Get Real-time Insights: FDA 483s & Warning letters.
Uncover Trends: FDA Investigator profiles & Observations.
Stay Compliant: Manage risks proactively.

Annual Product Quality Review

Explore essential insights on batch release processes to enhance compliance and quality. Dive into our article for practical guidance and best practices.

Annual Product Quality Review

Overview

22
Form 483s Issued
1
483s converted to WL
22
Total Observation
Form 483s Issued
+74 from last period

Recent Form 483s & Warning Letters

Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
09 May 2025
LEESAR, INC
Drugs
21 Jun 2024
Brands International Corporation
Drugs
14 Nov 2023
Carma Laboratories, Inc.
Drugs
18 Oct 2023
XYZ Pharmaceuticals
Drugs
14 Oct 2023
XYZ Pharmaceuticals Inc.
Drugs

Top FDA Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Jane Smith
11
0
John Doe
11
0
José E Melendez
3
0
Gavin T Cua
2
0
Nibin Varghese
2
1

Key Observations

TITLE/ COMPANY Issue Date Status Details
Records are not maintained so that data therein can be reviewed at least annually to evaluate the quality standards of each drug product to determine the need for changes in specifications or manufacturing or control procedures.
LEESAR, INC
09 May 2025 Normal Justification: The issue is directly linked to the lapses in carrying out and recording the Annual Product Quality Review, critical for maintaining drug quality.
Excerpt: your firm does not maintain written records for annual product reviews conducted for your aseptically produced drug products.
View Details
Records are not maintained so that data therein can be reviewed at least annually
Brands International Corporation
21 Jun 2024 Normal Justification: Annual Product Quality Review is directly implicated as the observation highlights deficiencies in conducting required evaluations.
Excerpt: Your firm has failed to perform annual product review for all the OTC products manufactured at your facility.
View Details
Written procedures are not followed for evaluations conducted to review records associated with batches
Carma Laboratories, Inc.
14 Nov 2023 Normal Justification: The deficiencies in conducting and closing APRs directly fall under Annual Product Quality Review as process type.
Excerpt: Specifically, Your firm failed to perform Annual Product Review (APR) for Domestic Lip Balm Stick and Domestic Lip Balm Tube for the year of 2022. According to your written procedure, individual APR are completed (b) (4) . Additionally, your procedure is deficient for the closure of APRs on a timely manner. For example, APR for Domestic Lip Balm Stick review period (1/1/2021 - 12/31/2021) was not completed until 12/29/2022.
View Details
Failure to ensure that all test procedures listed in the annual product review are completed
XYZ Pharmaceuticals
18 Oct 2023 Normal Justification: The annual product review process is key for evaluating ongoing product quality; missing test data directly affects this evaluation.
Excerpt: The 2022 Annual Product Review for Product B omitted the dissolution test results for three consecutive batches.
View Details
Failure to conduct at least an annual review, conducted under the supervision of the quality control unit, of records
XYZ Pharmaceuticals Inc.
14 Oct 2023 Normal Justification: The observation is linked to Annual Product Quality Review as it highlights missing documentation for 2 years, crucial for quality evaluations.
Excerpt: the annual product review for [redacted] for the past 2 years has not been documented.
View Details

Frequently Asked Questions

Heading 1

Heading 2

Heading 3

Heading 4

Heading 5
Heading 6

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Block quote

Ordered list

  1. Item 1
  2. Item 2
  3. Item 3

Unordered list

  • Item A
  • Item B
  • Item C

Text link

Bold text

Emphasis

Superscript

Subscript

Experience Leucine AI Powered pharma manufacturing
300+ pharma facilities worldwide use Leucine to stay compliant. Talk to one of our expert consultants at Leucine to learn how.
Related Resources

View and learn more about FDA Inspections
with our comprehensive list of resources